Allison Agwu MD, SCM






Associate Professor, Co-CRS leader


Allison Agwu is an Associate Professor of Adult and Pediatric Infectious Diseases at Johns Hopkins University School of Medicine. Dr. Agwu graduated from the University of Maryland School of Medicine in 1999 and completed a combined Internal Medicine and Pediatric Residency at University Hospitals of Cleveland/Rainbow Babies and Children's in Cleveland, Ohio in 2003. She then matriculated as the first combined adult/pediatric infectious diseases fellow at Johns Hopkins, which she completed in 2007. She came on faculty in 2007 with appointments in both pediatric and adult infectious diseases. Dr. Agwu's clinical and research interest is in HIV/AIDS and she has a special focus on adolescent and young adults living with HIV. She sees patients both in the pediatric and adult HIV clinics and as the founder and medical director of the Accessing Care Early (ACE) Clinic, has been integral to the transition of pediatric HIV infected patients to adult care. She also sees general pediatric infectious diseases consultations (in and outpatient). From a research perspective, Dr. Agwu’s overarching goal is to optimize outcomes for youth and to that aim deciphers health disparities and optimal ART treatment strategies (initiation and failure) and prevention of co-morbidities (e.g., inflammation) for youth living with HIV. Dr. Agwu has worked with the HIV Research Network for seven years, and has spearheaded the pediatric/adolescent working group agenda. Additionally, Dr. Agwu is the Principal Investigator of the Johns Hopkins sites of the International Maternal Pediatric and Adolescent AIDS Clinical Trials' Group (IMPAACT) and the Adolescent Trials’ Network (ATN), and the Co-Clinical Research Site leader of the JHU Adult AID Clinical Trials Group (ACTG) Unit. In addition she has chaired protocols examining strategies to address ART and morbidities in HIV infected pediatric, adolescent, and young adult patients. She is a member of the U.S. Department of Health and Human Services’ Pediatric Antiretroviral Treatment Guidelines.

  • Chair, IMPAACT Complications Scientific Committee (Jan 2016)
  • Co-chair, IMPAACT 2022
  • Co-investigator/protocol team member, Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of IMPAACT P1077 PROMISE: Promoting Maternal and Infant Survival Everywhere
  • Co-investigator, Biomarkers of Neurodevelopmental and Mental Health Outcomes in Perinatally HIV-Infected or Exposed Children and Adolescents
  • Agwu AL, Lindsey J, Ferguson K, Zhang H, Spector SA, Rudy BJ, Douglas S, Flynn P, Persaud D, and the Pediatric AIDS Clinical Trials Group 381 Study Team. Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch Following Initial Nonsuppressive Highly Active Antiretroviral Therapy. AIDS Patient Care and STDs 2008 May; 22(7).
  • Agwu AL, Jang SS, Korthuis PT, Warford R, and Gebo KA. Pregnancy Incidence and Outcomes Differ in Vertically and Behaviorally HIV-Infected Youth in a Multi-site Clinical Cohort. JAMA 2011; 305(5):468-470.   PMID: 21285423
  • Agwu AL, Ellen J,  Rutstein R,  Gaur AH, Siberry GK, Spector SA, Warford R, and Gebo
    KA.  Disparities in Antiretroviral Treatment: a Comparison of Behaviorally HIV-1 Infected Youth
    vs. Adults Meeting Treatment Criteria in the HIV Research Network.  Journal of the Acquired Immune Deficiency Syndrome 2011; 58(1): 100-107.  PMID: 21637114
  • Agwu AL, James Bethel, Lisa B. Hightow-Weidman, John W. Sleasman, Craig M. Wilson Bret Rudy, and Bill G. Kapogiannis for the ATN 061 team. Substantial Multiclass Transmitted Drug Resistance and Drug-Relevant Polymorphisms Among Treatment-naïve Youth: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Study. AIDS Patient Care and STDs 2012; 26(4): 193-6. PMID:  22563607
  • Wong FL,  Hsu AJ, Pham PA, Siberry GK, Hutton N, and Agwu AL*. Antiretroviral Regimens in Highly Treatment Experienced Perinatally HIV-Infected Youth: What is the Optimal Strategy? Pediatric Infectious Diseases Journal 2012; 31(12): 1279-83.  PMID:  22926213
  • Agwu AL, Fleishman JA, Rutstein R, Korthuis PT, and Gebo KA.  Changes in Advanced Immunosuppression and Detectable Viremia among Perinatally HIV-Infected Youth in the Multi-site U.S. HIV Research Network. Journal of the Pediatric Infectious Diseases Society. August 2013; 2(3): 215- 223.
  • Agwu AL*, Neptune A, Voss C, Yehia BR, and Rutstein R for the HIV Research Network. CD4 Counts of Non-Perinatally HIV-Infected Youth and Young Adults Presenting for HIV Care were Essentially Unchanged between 2002 and 2010. JAMA Pediatrics 2014; 168(4): 381
  • Farmer C, Yehia B, Fleishman J, Rutstein R, Gebo KA, and Agwu AL* for the HIV Research Network.  Factors Associated with Retention among Non-Perinatally HIV-Infected Youth at HIV
    Research Network Sites between 2002 and 2011. Journal of the Pediatric Infectious Diseases Society (in press)


Leadership Committees

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More